Covaxin For Children
- All
- News
- Videos
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covaxin Cleared For 6-12 Age Group, Corbevax For 5-12-Year-Olds
The Drugs Controller General of India (DCGI) today gave emergency use authorisation to Bharat Biotech's Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.
-
"Great Going, My Friends": Health Minister After 2 Crore Teens Vaccinated
Over 2 crore teenagers in the age group of 15-18 years have received their first dose of COVID-19 vaccine in less than a week of the inoculation drive being launched for children, Union Health Minister Mansukh Mandaviya said today.
-
Day 1 Of Vaccination For Age 15-18 Amid 3rd Wave, Over 40 Lakh Jabbed
Vaccination opened for teens in the 15 to 18 age group today amid the third Covid wave in India as cases surge in multiple cities. Over 40 lakh teens got their first dose on Day 1, Health Minister Dr Mansukh Mandaviya said.
-
1st Covaxin Dose For 15-18 Years Category Within Jan 9: Assam Minister
The Assam government is targeting to administer the first dose of Covaxin to all teenagers in the 15-18 years age group within seven days from the beginning of the national inoculation drive for this category from January 3, Health Minister Keshab Ma
-
Data From Trials On 2-18-Year-Olds Very Encouraging: Covaxin Maker
Bharat Biotech today announced that Covaxin, its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III trials.
-
Covaxin Showed Good Response In Children During Trials: Covid Panel Chief
Covaxin has shown that it has a very good immune response in children in trials, Chairman of India's COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) Dr NK Arora said on Sunday.
-
Centre's Decision To Vaccinate Children "Unscientific": Senior AIIMS Epidemiologist
A senior epidemiologist at AIIMS who is the principal investigator of Covaxin trials for adults and children at the institute on Sunday termed the Centre's decision to vaccinate children against Covid "unscientific".
-
Covaxin Cleared For Children Above 12 By Drug Regulator
Bharat Biotech's COVID-19 vaccine Covaxin has been approved for emergency use on children between the ages of 12 and 18 by the Drugs Controller General of India (DCGI), sources said.
-
Bharat Biotech's Covaxin Approval Requested In US For Children Below 18
US company Ocugen announced Friday that it had asked authorities for emergency use authorization for Covid-19 vaccine Covaxin, which was developed in India, for ages 2 to 18.
-
On Covaxin Approval For Kids, Pregnant Women, WHO Chief Scientist Says...
The clearance for using Covaxin on children will take much less time, World Health Organization (WHO) chief scientist Dr Soumya Swaminathan told NDTV after the Bharat Biotech-manufactured vaccine's Emergency Use Listing.
-
Covaxin Gets WHO Approval, Finally
The WHO has granted Covaxin an emergency use listing, sources said Wednesday, which means the 'made-in-India' vaccine will be recognised by other countries and Indians who received the shot need not self-quarantine or face restrictions abroad.
-
Evaluation Underway, Says Centre On Covid Vaccine For Children In India
Covid vaccine for children is currently being evaluated, Union Minister of State for Health and Family Welfare Bharati Pravin Pawar said Tuesday, adding, the vaccine will be launched after expert recommendation and approval from the drug regulator.
-
Covaxin Shot Recommended For Children In India
An expert panel on Tuesday recommended Covaxin - Bharat Biotech's COVID-19 vaccine for use on children, pending final clearance by the Drug Controller General of India, between the ages of two and 18.
-
Paediatric Covaxin: Bharat Biotech Completes Phase 2/3 Trials
Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech, Krishna Ella said.
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covaxin Cleared For 6-12 Age Group, Corbevax For 5-12-Year-Olds
The Drugs Controller General of India (DCGI) today gave emergency use authorisation to Bharat Biotech's Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.
-
"Great Going, My Friends": Health Minister After 2 Crore Teens Vaccinated
Over 2 crore teenagers in the age group of 15-18 years have received their first dose of COVID-19 vaccine in less than a week of the inoculation drive being launched for children, Union Health Minister Mansukh Mandaviya said today.
-
Day 1 Of Vaccination For Age 15-18 Amid 3rd Wave, Over 40 Lakh Jabbed
Vaccination opened for teens in the 15 to 18 age group today amid the third Covid wave in India as cases surge in multiple cities. Over 40 lakh teens got their first dose on Day 1, Health Minister Dr Mansukh Mandaviya said.
-
1st Covaxin Dose For 15-18 Years Category Within Jan 9: Assam Minister
The Assam government is targeting to administer the first dose of Covaxin to all teenagers in the 15-18 years age group within seven days from the beginning of the national inoculation drive for this category from January 3, Health Minister Keshab Ma
-
Data From Trials On 2-18-Year-Olds Very Encouraging: Covaxin Maker
Bharat Biotech today announced that Covaxin, its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III trials.
-
Covaxin Showed Good Response In Children During Trials: Covid Panel Chief
Covaxin has shown that it has a very good immune response in children in trials, Chairman of India's COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) Dr NK Arora said on Sunday.
-
Centre's Decision To Vaccinate Children "Unscientific": Senior AIIMS Epidemiologist
A senior epidemiologist at AIIMS who is the principal investigator of Covaxin trials for adults and children at the institute on Sunday termed the Centre's decision to vaccinate children against Covid "unscientific".
-
Covaxin Cleared For Children Above 12 By Drug Regulator
Bharat Biotech's COVID-19 vaccine Covaxin has been approved for emergency use on children between the ages of 12 and 18 by the Drugs Controller General of India (DCGI), sources said.
-
Bharat Biotech's Covaxin Approval Requested In US For Children Below 18
US company Ocugen announced Friday that it had asked authorities for emergency use authorization for Covid-19 vaccine Covaxin, which was developed in India, for ages 2 to 18.
-
On Covaxin Approval For Kids, Pregnant Women, WHO Chief Scientist Says...
The clearance for using Covaxin on children will take much less time, World Health Organization (WHO) chief scientist Dr Soumya Swaminathan told NDTV after the Bharat Biotech-manufactured vaccine's Emergency Use Listing.
-
Covaxin Gets WHO Approval, Finally
The WHO has granted Covaxin an emergency use listing, sources said Wednesday, which means the 'made-in-India' vaccine will be recognised by other countries and Indians who received the shot need not self-quarantine or face restrictions abroad.
-
Evaluation Underway, Says Centre On Covid Vaccine For Children In India
Covid vaccine for children is currently being evaluated, Union Minister of State for Health and Family Welfare Bharati Pravin Pawar said Tuesday, adding, the vaccine will be launched after expert recommendation and approval from the drug regulator.
-
Covaxin Shot Recommended For Children In India
An expert panel on Tuesday recommended Covaxin - Bharat Biotech's COVID-19 vaccine for use on children, pending final clearance by the Drug Controller General of India, between the ages of two and 18.
-
Paediatric Covaxin: Bharat Biotech Completes Phase 2/3 Trials
Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech, Krishna Ella said.
